So testing commencing today with hopefully some really great results in the next few days or so. Hopefully laying the foundations for W2 and W3 and a nice re rating.
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress
Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling
